诺和诺德(NVO.US)跌3.3%，报38.48美元。消息面上，诺和诺德因未有报告服用减肥药物Ozempic的患者出现的所有疑似副作用，接获美国食品药物管理局(FDA)的警告信。FDA在信中指出，病例中包括两宗死亡和一宗自杀，患者均有接受司美格鲁肽(semaglutide)治疗，该药物是Ozempic及Wegovy的通用名。FDA并未明确指出该等死亡或其他副作用是否与该药物有关。(格隆汇)
诺和诺德(NVO.US)跌3.3%，报38.48美元。消息面上，诺和诺德因未有报告服用减肥药物Ozempic的患者出现的所有疑似副作用，接获美国食品药物管理局(FDA)的警告信。FDA在信中指出，病例中包括两宗死亡和一宗自杀，患者均有接受司美格鲁肽(semaglutide)治疗，该药物是Ozempic及Wegovy的通用名。FDA并未明确指出该等死亡或其他副作用是否与该药物有关。(格隆汇)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.